VACTANE: Vascular Access Complications for Therapeutic Apheresis in Nephrology
Study Details
Study Description
Brief Summary
The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.
Complications may include arterio-veinous fistula or graft (AVF or AVG) thrombosis with or without known stenosis; AVF or AVG or central veinous catheter (CVC) infections and CVC dysfunctions.
We may enroll all patients receveing therapeutic apheresis for nephrologic indications in our unit:
Nephrologics complications include :
-
acute or active antibody mediated rejection (ABMR),
-
Goodpasture disease,
-
ANCA vasculitis,
-
thrombotic angiopathy (TMA),
-
Focal segmental glomerulosclerosis (FSGS),
-
HLA or ABO desensitization for kidney transplantation.
Data inclusion period is from June 2020 to June 2022.
The aim of the study is to describe the proportion and type of complication in our population of patient receving therapeutic apheresis. We will study the risk factors that are associated with this complications.
The second aim of the study is to describe the population of patient receving therapeutic apheresis in our unit and in our region.
Study Design
Outcome Measures
Primary Outcome Measures
- Vascular access Complication rate in therapeutic apheresis [june 2020 june 2022]
% of patient with Vascular access Complication
Secondary Outcome Measures
- Description of population enrolled [june 2020 june 2022]
Description of population treated by therapeutic apheresis in Northeast France
- Comparison of complications rate with literature datas [june 2020 june 2022]
Eligibility Criteria
Criteria
Inclusion Criteria:
- patients in nephrology receiveing apheresis treatment by filtration or double filtration
Exclusion Criteria:
-
apheresis treatment for other indications
-
centrifugation apheresis treatment
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Central Hospital | Nancy | France | 54000 |
Sponsors and Collaborators
- Central Hospital, Nancy, France
Investigators
- Principal Investigator: Luc Frimat, MD PhD, CHRU NANCY DRCI
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- VACTANE